Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT05103917 Enrolling by invitation - Clinical trials for Triple Negative Breast Cancer

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Start date: July 21, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Objectives Phase 1b Primary Objectives: To evaluate the safety and tolerability of X4P-001 combined with toriplimab in patients with locally advanced or metastatic TNBC Secondary Objectives: 1. To characterize the pharmacokinetics (PK) profile of X4P-001 alone or combined with toriplimab 2. To characterize the antitumor activity of X4P-001 in combination with toriplimab in patients with locally advanced or metastatic TNBC(according to RECIST 1.1) 3. To characterize the overall survival of X4P-001 in combination with toriplimab in patients with locally advanced or metastatic TNBC 4. To characterize the immunogenicity of toriplimab when administrated in combination with X4P-001

NCT ID: NCT05055375 Enrolling by invitation - Breast Cancer Clinical Trials

The Psychology of Chinese Breast Cancer Patients

Start date: April 25, 2019
Phase:
Study type: Observational

Earlier diagnosis of breast cancer in women and the use of systemic adjuvant therapy have increased the likelihood of long term, disease free survival.women who remain free of breast cancer seem to have levels of functioning and quality of life that are comparable to those of the general female population.It will be assessed the psychology status of women with breast cancer using a clinical interview,

NCT ID: NCT05012813 Enrolling by invitation - Breast Carcinoma Clinical Trials

Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer

Start date: July 19, 2022
Phase: N/A
Study type: Interventional

This clinical trial studies the feasibility of simulating forest therapy using humidified wood or fragrant oils, in improving immune cells, like natural killer cells, number and activity, and their downstream proteins, perforin and granulysin in patients with stage I-III breast or prostate cancer who completed chemo- and/or radiation therapy. The knowledge gained from this study may help cancer patients who have compromised immune systems and who also cannot participate in outdoor activities like exercise or forest walks.

NCT ID: NCT04933266 Enrolling by invitation - Breast Cancer Clinical Trials

Subpectoral Plexus Block With Multi-level TPVB for Surgical Anesthesia During Primary Breast Cancer Surgery

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to compare two different doses of local anesthetics (10ml vs 20ml of 0.25% levobupivacaine) for subpectoral plexus block (SPPB) in addition to ultrasound guided multi-level of thoracic paravertebral block (m-TPVB) for surgical anaesthesia for major primary breast cancer surgery.

NCT ID: NCT04929197 Enrolling by invitation - Breast Cancer Clinical Trials

Evaluation of the Feasibility of Developing Personalized Breast Cancer Radiotherapy Assistive Device With 3D Printing

PERSBRA
Start date: April 21, 2016
Phase: N/A
Study type: Interventional

Breast cancer is the most common malignancy among women worldwide. For early stage breast cancer, adjuvant radiotherapy is essential to minimize loco-regional disease recurrence. However, significant portions of the heart and the lungs are exposed to low dose radiation during radiotherapy, which result in stochastic side effects among breast cancer survivors. Inspired by 3D printing technology, we approached this issue with an in-house made PERSonalized BReAst holder system (PERSBRA). PERSBRA is composed of a 3D-printed plastic holder covering the whole breast and an air-filled interface. Its main function is to reproducibly adjust the breast position to decrease heart and lung radiation exposure in tangential fields. Here we propose to measure the performance of PERSBR in terms of radiation dosimetry in 50 patients receiving scheduled whole breast irradiation. For customized PERSBRA, body shape of the patient with or without a bustier corset will be captured with a handheld 3D scanner and input into a 3D printer for PERSBRA design and manufacturing. A participant will receive two more CT scans in addition to the simulation scan with PERSBRA in place before the first and the sixth fractions of irradiation. These images will be analyzed for dosimetric parameters in the presence/absence of PERSBRA as well as position reproducibility. The data will provide proof-of-principle evidence for the clinical utility of PERSBRA and will facilitate its further refinement.

NCT ID: NCT04928014 Enrolling by invitation - Healthy Clinical Trials

Validation of a Tear-based Screening Assay for Breast Cancer

Start date: June 1, 2021
Phase:
Study type: Observational

This study will explore and better understand the value, usage, and benefits of a tear-based screening test for breast cancer as a supplemental tool for screening mammograms. This tear-based screening test was developed and validated by Namida Lab, Inc., a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified lab.

NCT ID: NCT04914494 Enrolling by invitation - Breast Cancer Clinical Trials

Cancer Predictive Score on Breast MRI

Start date: January 1, 2021
Phase:
Study type: Observational

Sometimes, breast ultrasound and mammographic can't be diagnose suspsious lesions ( no substratum). So a MRI-guided breast biopsy is perfomed and disclosed ultimately benign lesions. The aim of this retrospective study is to establish a predictive MRI score of occult breast lesions by mammography and ultrasound.

NCT ID: NCT04862078 Enrolling by invitation - Breast Cancer Clinical Trials

Shared Decision Making in Surveillance for Distant Metastasis in Breast Cancer

SMART-FU
Start date: July 6, 2021
Phase: N/A
Study type: Interventional

In this study, clinical impacts of shared decision making between physicians and patients in strategy of surveillance for asymptomatic patients who ended the primary treatments on quality of life would be investigated

NCT ID: NCT04842617 Enrolling by invitation - Clinical trials for Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer

Phase III Study :SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative

Start date: April 30, 2021
Phase: Phase 3
Study type: Interventional

The study is to evaluate the efficacy and safety of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative. To observe the PK characteristics of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative.

NCT ID: NCT04783402 Enrolling by invitation - Breast Neoplasms Clinical Trials

Telehealth Program to Prevent Cancer and Chemotherapy-related Cognitive Impairment.

Start date: October 31, 2020
Phase: N/A
Study type: Interventional

The present randomized controlled trial has the main objective to study the effects of a videoconferenced occupational therapy program in preventing cancer and chemotherapy-related cognitive impairment and other health outcomes, as well as in improving quality of live and occupational performance of women undergoing chemotherapy for breast cancer.